iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
15 nov. 2021 13h00 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
08 nov. 2021 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Acquires FastPharming Manufacturing Facility®
03 nov. 2021 16h47 HE
|
iBio, Inc.
- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67% - BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
26 oct. 2021 08h35 HE
|
iBio, Inc.
BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
27 sept. 2021 07h30 HE
|
iBio, Inc.
Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming® and GlycaneeringTM...
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
20 sept. 2021 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
20 sept. 2021 07h30 HE
|
iBio, Inc.
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
iBio Appoints William D. Clark to its Board of Directors
26 août 2021 07h00 HE
|
iBio, Inc.
BRYAN, Texas, Aug. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
25 août 2021 07h30 HE
|
iBio, Inc.
– iBio licenses a novel antibody targeting regulatory T cells – – Company secures option to license additional antibodies developed with RubrYc’s predictive algorithms – – iBio acquires an equity...